Generation of Raw RPPA Data and Their Conversion to Analysis-Ready Data.

Area of Science:

• Proteomics
• Biotechnology
• Cancer Research

Background:

• Reverse phase protein array (RPPA) is a quantitative, antibody-based technology for functional proteomics.
• It offers high-throughput analysis similar to Western blots but with broader applications.
• RPPA is valuable for pharmacodynamics, drug sensitivity, biomarker discovery, and patient prognosis.

Purpose of the Study:

• To describe the RPPA technology, including its limitations and solutions.
• To detail the process of obtaining raw RPPA data and converting it into analysis-ready data.
• To validate the RPPA platform and presented methods using cancer cell line biomarkers and drug responses.

Main Methods:

• Description of the RPPA technology and its procedural similarities to Western blotting.
• Discussion of steps for raw data acquisition and quality control.
• Validation of the platform through analysis of cancer cell line data.

Main Results:

• The study outlines methods to overcome RPPA limitations.
• Successful conversion of raw RPPA data into high-quality, analysis-ready datasets.
• Validation of RPPA utility by confirming known biomarkers and drug responses in cancer cell lines.

Conclusions:

• RPPA is a powerful tool for functional proteomics with diverse applications in cancer research.
• The presented methods enhance data quality and reliability for RPPA studies.
• RPPA facilitates biomarker discovery and assessment of therapeutic responses, aiding in personalized medicine.